NORD Intervention In EPO Appeal Seeks Consideration Of Amgen Epogen Cost
Executive Summary
The National Organization for Rare Disorders is attempting to have the issue of drug pricing play a role in the appeal of the erythropoietin patent case Amgen v. Aventis/Transkaryotic Therapies.
You may also be interested in...
Aventis/TKT Dynepo Regulatory Review Commences, Patent Suit Continues
The regulatory pathway of gene-activated erythropoietin Dynepo is evidence that the product is not equivalent to Amgen's Epogen, Aventis Chief Scientific Officer Frank Douglas, MD/PhD, said July 18 in Boston federal court.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials